No causative genes are listed in this packet, and the packet does not certify a molecular mechanism. The packet lists an autosomal dominant inheritance pattern, but because no associated gene is listed and no information on recurrence, penetrance, or family implications is certified, that pattern is not elaborated here.

According to the MONDO definition, diagnostic procedures include ophthalmoscopic examination, fluorescein angiography, and ultrasound. Other diagnostic criteria are not certified in this packet.

According to the MONDO definition, treatment includes surgical excision of the eye, iridocyclectomy, and tumor resection, with radiotherapy or photocoagulation described as more recent treatments. The packet lists two FDA-approved products with active market status: KIMMTRAK (tebentafusp), approved under a BLA on 2022-01-25, and HEPZATO KIT (melphalan hydrochloride), approved under an NDA on 2023-08-14. The packet also lists orphan drug designations for several investigational products, and one entry for selumetinib is marked withdrawn; a designation is not an approval. Stage-specific treatment context is not certified in this packet.

Prognosis is not certified in this packet, which provides no natural history information for this condition.

According to ClinicalTrials.gov records summarized in the packet, active clinical trials are listed for this condition. An example is NCT07364474, a trial of immune response to percutaneous hepatic perfusion with melphalan for ocular melanoma metastatic to the liver, sponsored by Massachusetts General Hospital, recruiting, with dates from 2026-01-27 to 2028-09-01. A trial title does not establish that an intervention is beneficial. No registries or patient organizations are listed in this packet.